News

Improved Brain Immunotherapy Delivery Strategy Uses Brain’s Natural Plumbing System, Study Reports

A new approach for delivering antibody-based therapeutics to the brain by exploiting the fluid surrounding the brain’s blood vessels was proposed in a recent preclinical study. This improved brain immunotherapy delivery strategy has implications for treating diseases of the brain and spinal cord, including Alzheimer’s, Parkinson’s, amyotrophic lateral sclerosis…

Phase 1 Trial to Test AL002, Targeting Brain’s Immune System, as Way of Treating Alzheimer’s

Alector’s candidate immune system-targeting therapy for Alzheimer’s disease, called AL002, will be evaluated for safety and tolerability in a first Phase 1 clinical trial, the company announced. AL002 is an antibody that targets and activates TREM2 (triggering receptor expressed on myeloid cells 2), a receptor selectively expressed on microglia — a group…